Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Other Operating Expenses (2019 - 2020)

Historic Other Operating Expenses for Keros Therapeutics (KROS) over the last 2 years, with Q1 2020 value amounting to -$1.5 million.

  • Keros Therapeutics' Other Operating Expenses fell 14668.87% to -$1.5 million in Q1 2020 from the same period last year, while for Dec 2020 it was -$1.5 million, marking a year-over-year increase of 4188.77%. This contributed to the annual value of -$1.5 million for FY2020, which is 4188.77% up from last year.
  • Per Keros Therapeutics' latest filing, its Other Operating Expenses stood at -$1.5 million for Q1 2020, which was down 14668.87% from -$78000.0 recorded in Q4 2019.
  • Keros Therapeutics' 5-year Other Operating Expenses high stood at -$78000.0 for Q4 2019, and its period low was -$1.5 million during Q1 2020.